Director/PDMR Shareholding

RNS Number : 3423H

Mediclinic International plc

06 June 2017

 

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic", the "Company" or the "Group")

6 June 2017

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

Vesting of awards under the Company's Forfeitable Share Plan

The awards of ordinary shares in Mediclinic (the "Shares") set out in the table below, granted on 31 July 2014, vested under the Company's Forfeitable Share Plan on 31 May 2017.

Name	Director/ PDMR	Number of Shares vested	Number of Shares sold at ZAR 130.44 per share	Number of Shares retained1
Danie Meintjes	Director	49,423	0	49,423
Gert Hattingh	PDMR	14,734	0	14,734
Koert Pretorius	PDMR	19,806	19,806	0
David Hadley	PDMR	9,778	9,778	0
Dr Ole Wiesinger1	PDMR	17,506	0	17,506
Dr Ronnie van der Merwe	PDMR	16,507	16,507	0

1.     Dr Wiesinger was granted a conditional right to 17,506 Shares under the Country Schedule to the Forfeitable Share Plan on 31 July 2014. On 1 June 2017, Dr Wiesinger elected to receive the award in Shares, which he received on 5 June 2017.

The following notification made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation relates to the Company's Forfeitable Share Plan.

 

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Daniël Petrus Meintjes
2.	Reason for the notification
a)	Position / status	Chief Executive Officer of the Company
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Vesting of award over 49,423 ordinary shares awarded under the Company's Forfeitable Share Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) Nil cost 49,423
d)	Aggregated information Aggregated volume Price	49,423 Nil cost
e)	Date of the transaction	1 June 2017
f)	Place of the transaction	Johannesburg Stock Exchange

 

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Gert C Hattingh
2.	Reason for the notification
a)	Position / status	Chief Corporate Services Officer of the Company
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Vesting of award over 14,734 ordinary shares awarded under the Company's Forfeitable Share Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) Nil cost 14,734
d)	Aggregated information Aggregated volume Price	14,734 Nil cost
e)	Date of the transaction	1 June 2017
f)	Place of the transaction	Johannesburg Stock Exchange

 

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Koert Hendrik S Pretorius
2.	Reason for the notification
a)	Position / status	Chief Executive Officer - Mediclinic Southern Africa
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	1.  Vesting of award over 19,806 ordinary shares awarded under the Company's Forfeitable Share Plan 2.   Sale of 19,806 ordinary shares.
c)	Price(s) and volume(s)	Price(s) Volume(s) 1.   Nil cost 1.   19,806 2.   ZAR 130.44 2.   19,806
d)	Aggregated information Aggregated volume Price	1.   19,806 2.   19,806 1.   Nil cost 2.   ZAR 130.44
e)	Date of the transaction	1 June 2017
f)	Place of the transaction	Johannesburg Stock Exchange

 

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	David J Hadley
2.	Reason for the notification
a)	Position / status	Chief Executive Officer - Mediclinic Middle East
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	1.  Vesting of award over 9,778 ordinary shares awarded under the Company's Forfeitable Share Plan 2.  Sale of 9,778 ordinary shares.
c)	Price(s) and volume(s)	Price(s) Volume(s) 1.   Nil cost 1.   9,778 2.   ZAR 130.44 2.   9,778
d)	Aggregated information Aggregated volume Price	1.   9,778 2.   9,778 1.   Nil cost 2.   ZAR 130.44
e)	Date of the transaction	1 June 2017
f)	Place of the transaction	Johannesburg Stock Exchange

 

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Dr Thorsten Ole Wiesinger
2.	Reason for the notification
a)	Position / status	Chief Executive Officer - Hirslanden
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Vesting of conditional right to 17,506 Shares under the Country Schedule to the Forfeitable Share Plan on 31 July 2014
c)	Price(s) and volume(s)	Price(s) Volume(s) Nil cost 17,506
d)	Aggregated information Aggregated volume Price	17,506 Nil cost
e)	Date of the transaction	5 June 2017
f)	Place of the transaction	Johannesburg Stock Exchange

 

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Dr Carel A van der Merwe
2.	Reason for the notification
a)	Position / status	Chief Clinical Officer of the Company
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	1.  Vesting of award over 16,507 ordinary shares awarded under the Company's Forfeitable Share Plan 2.  Sale of 16,507 ordinary shares.
c)	Price(s) and volume(s)	Price(s) Volume(s) 1.   Nil cost 1.   16,507 2.   ZAR 130.44 2.   16,507
d)	Aggregated information Aggregated volume Price	1.   16,507 2.   16,507 1.   Nil cost 2.   ZAR 130.44
e)	Date of the transaction	1 June 2017
f)	Place of the transaction	Johannesburg Stock Exchange

About Mediclinic International plc

Mediclinic is an international private healthcare group with operating platforms in Southern Africa (South Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE listed and UK-based private healthcare group.

Mediclinic comprises 74 hospitals and 37 clinics. Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds in total; Hirslanden operates 16 private acute care facilities and 4 clinics in Switzerland with more than 1 600 inpatient beds; and Mediclinic Middle East operates 6 hospitals and 31 clinics with more than 700 inpatient beds in the United Arab Emirates.

During February 2016, the combination of the Company (previously named Al Noor Hospitals Group plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic International Limited was completed. Mediclinic International Limited was a South African based international private healthcare group founded in 1983 and listed on the JSE, the South African stock exchange, since 1986, with operations in South Africa, Namibia, Switzerland and the United Arab Emirates (mainly in Dubai). The combination resulted in the renaming of the enlarged group to Mediclinic International plc.

Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in South Africa and the NSX in Namibia.

For further information, please contact:

Capita Company Secretarial Services Limited

Victoria Dalby

[phone]

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

[e-mail]

[phone]

Media queries

FTI Consulting

Brett Pollard/Debbie Scott (UK)

[phone]

Frank Ford (South Africa)

[phone]

Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom

Website: www.mediclinic.com

Corporate broker: Morgan Stanley & Co International plc

JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd

 

END

 

 

DSHBLGDLXXGBGRL